Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | SVP & General Counsel | April 10, 2026 | April 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date April 10, 2026 · Filed April 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 153,655 |
Ending reported balance
After 2026-04-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-10 · Exercise / conversion · Acquired 9,925 · Balance 157,967 Row 2 · 2026-04-10 · Tax withholding · Disposed 4,312 · Balance 153,655 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,925 |
Reported balance
After 2026-04-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-10 · Exercise / conversion · Disposed 9,925 · Balance 9,925 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 10, 2026 Filed Apr 14, 2026 22:17 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 9,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000007 · wk-form4_1776205072.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,925 Underlying: Class A Common Stock · 9,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 22:17 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 4,312 | $9.06 | $39,066.72 |
DisclosureSEC source: 0001835184-26-000007 · wk-form4_1776205072.xml · nonDerivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,655 Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 22:17 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 9,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000007 · wk-form4_1776205072.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · derivative · entry 10 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Underlying: Class A Common Stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 8,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · derivative · entry 9 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. F4 · derivative.expiration_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 92,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · derivative · entry 8 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 Underlying: Class A Common Stock · 92,000 shares Expires 2036-03-13 F3 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 83,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · derivative · entry 7 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,000 Underlying: Class A Common Stock · 83,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 3,802 | $8.62 | $32,773.24 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · nonDerivative · entry 4 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,042 Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · nonDerivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 3,861 | $8.62 | $33,281.82 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · nonDerivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,094 Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 8,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:28 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 12,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000003 · wk-form4_1771457326.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,960 Underlying: Class A Common Stock · 12,980 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:28 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 6,327 | $8.27 | $52,324.29 |
DisclosureSEC source: 0001835184-26-000003 · wk-form4_1771457326.xml · nonDerivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,069 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:28 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 12,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000003 · wk-form4_1771457326.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 21:50 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 2,958 | $7.57 | $22,392.06 |
DisclosureSEC source: 0001578563-25-000218 · wk-form4_1744753804.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,416 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 10, 2025 pursuant to a standing 10b5-1 instruction adopted on April 10, 2023. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $7.145 to $7.890, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 21:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 9,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000210 · wk-form4_1744407039.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,850 Underlying: Class A Common Stock · 9,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 21:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 9,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000210 · wk-form4_1744407039.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:33 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 2,615 | $9.75 | $25,496.25 |
DisclosureSEC source: 0001578563-25-000184 · wk-form4_1742333627.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,449 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on March 14, 2025 pursuant to a standing 10b5-1 instruction adopted on March 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $9.56 to $10.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 14, 2025 23:05 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 8,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000176 · wk-form4_1741993549.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,886 Underlying: Class A Common Stock · 8,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. F2 · derivative.expiration_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. Read SEC document |
| March 14, 2025 Filed Mar 14, 2025 23:05 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 8,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000176 · wk-form4_1741993549.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2025 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · derivative · entry 6 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Common Stock · 40,000 shares Expires 2035-03-14 F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 14, 2025 Filed Mar 17, 2026 21:01 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001835184-26-000005 · wk-form4_1773781286.xml · derivative · entry 5 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Class A Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 00:00 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 4,380 | $10.19 | $44,632.20 |
DisclosureSEC source: 0001578563-25-000120 · wk-form4_1740096052.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,178 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on February 15, 2025 pursuant to a standing 10b5-1 instruction adopted on March 15, 2024. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $9.74 to $10.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:00 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 12,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000073 · wk-form4_1739919607.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,940 Underlying: Class A Common Stock · 12,980 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:00 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 12,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000073 · wk-form4_1739919607.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 21:54 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 5,848 | $10.53 | $61,579.44 |
DisclosureSEC source: 0001578563-24-000515 · wk-form4_1735250082.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,578 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on December 20, 2024 pursuant to a standing 10b5-1 instruction adopted on June 20, 2023. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $10.41 to $10.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 22:27 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 19,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000506 · wk-form4_1734992859.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 19,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested 50% on the twelve-month anniversary of the date of grant, and the remaining 50% vested on the eighteenth-month anniversary of the date of grant, subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vested 50% on the twelve-month anniversary of the date of grant, and the remaining 50% vested on the eighteenth-month anniversary of the date of grant, subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 22:27 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 19,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000506 · wk-form4_1734992859.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 20:58 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 5,904 | $5.57 | $32,885.28 |
DisclosureSEC source: 0001578563-24-000325 · wk-form4_1719349115.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,576 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on June 20, 2024 pursuant to a standing 10b5-1 instruction adopted on June 20, 2023. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $5.515 to $5.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 00:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 19,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000317 · wk-form4_1719276344.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,850 Underlying: Class A Common Stock · 19,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest 50% on the twelve-month anniversary of the date of grant, and the remaining 50% shall vest on the eighteenth-month anniversary of the date of grant, subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest 50% on the twelve-month anniversary of the date of grant, and the remaining 50% shall vest on the eighteenth-month anniversary of the date of grant, subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 00:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 19,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000317 · wk-form4_1719276344.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2024 Filed Jun 21, 2024 20:25 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 11,308 | $5.84 | $66,038.72 |
DisclosureSEC source: 0001578563-24-000311 · wk-form4_1719001540.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,630 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on June 15, 2024 pursuant to a standing 10b5-1 instruction adopted on March 15, 2024. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $5.525 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 21:40 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 34,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000301 · wk-form4_1718746851.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 34,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 15, 2024. F2 · derivative.expiration_date: The RSUs vested on June 15, 2024. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 21:40 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 34,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000301 · wk-form4_1718746851.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 22:00 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 3,054 | $4.75 | $14,506.50 |
DisclosureSEC source: 0001578563-24-000202 · wk-form4_1713218427.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,242 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 10, 2024 pursuant to a standing 10b5-1 instruction adopted on April 10, 2023. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $4.53 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:53 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 9,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000192 · wk-form4_1712955210.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,775 Underlying: Class A Common Stock · 9,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:53 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 9,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-24-000192 · wk-form4_1712955210.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 22:41 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 3,125 | $5.46 | $17,062.50 |
DisclosureSEC source: 0001578563-24-000174 · wk-form4_1710974500.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,371 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on March 14, 2024 pursuant to a standing 10b5-1 instruction. F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple stockholders in multiple transactions at prices ranging from $5.13 to $5.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 22, 2024 21:21 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001578563-24-000179 · wk-form4_1711142495.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Class A Common Stock · 120,000 shares Expires 2034-03-15 F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 15, 2024 Filed Mar 22, 2024 21:21 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 34,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000179 · wk-form4_1711142495.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,696 Underlying: Class A Common Stock · 34,696 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest on June 15, 2024, subject to the Reporting Person continuing in service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest on June 15, 2024, subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 15, 2024 Filed Mar 22, 2024 21:21 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 51,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000179 · wk-form4_1711142495.xml · derivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,920 Underlying: Class A Common Stock · 51,920 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 8,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000168 · wk-form4_1710809241.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,772 Underlying: Class A Common Stock · 8,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. F2 · derivative.expiration_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 8,886 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-24-000168 · wk-form4_1710809241.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:57 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 39,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000054 · primary_doc.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,700 Underlying: Class A Common Stock · 39,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest 50% on the twelve-month anniversary of the date of grant, and the remaining 50% shall vest on the eighteenth-month anniversary of the date of grant, subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest 50% on the twelve-month anniversary of the date of grant, and the remaining 50% shall vest on the eighteenth-month anniversary of the date of grant, subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| April 10, 2023 Filed Apr 13, 2023 01:03 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 103,600 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001578563-23-000020 · primary_doc.xml · derivative · entry 4 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,600 Underlying: Class A Common Stock · 103,600 shares Expires 2033-04-10 F3 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| April 10, 2023 Filed Apr 13, 2023 01:03 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 39,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000020 · primary_doc.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,700 Underlying: Class A Common Stock · 39,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 01:21 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 3,409 | $1.39 | $4,737.49 |
DisclosureSEC source: 0000899243-23-008794 · doc4.xml · nonDerivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,610 F2 · kind: Reflects shares sold to cover taxes upon the vesting of the RSUs on March 14, 2023 pursuant to a standing 10b5-1 instruction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.385 to $1.42, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 01:21 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 8,887 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008794 · doc4.xml · derivative · entry 4 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,658 Underlying: Class A Common Stock · 8,887 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. F4 · derivative.expiration_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 01:21 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 8,887 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-008794 · doc4.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 01:16 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 16,016 | $11.19 | $179,238.26 |
DisclosureSEC source: 0000899243-22-013966 · doc4.xml · nonDerivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,132 F2 · kind: Reflects shares sold to cover taxes upon the vesting of RSUs on April 1, 2022 pursuant to a standing 10b5-1 instruction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.0438 to $11.54, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.